We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roku, Inc. (ROKU - Free Report) , is involved in creating a streaming platform for delivering entertainment to television. Over the past 90 days, the Zacks Consensus Estimate for ROKU's full-year earnings has moved 13.04% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Wall Street will be looking for positivity from ROKU as it approaches its next earnings report date. Over the past month, the Zacks Consensus EPS estimate has moved 6.72%. According to our latest data, ROKU has moved higher by triple digits on a year-to-date basis. It looks to continue its solid performance.
JD.com, Inc. (JD - Free Report) , operates as an online direct sales company in China. It’s considered the Amazon of China. Investors will be hoping for strength from JD as it approaches its next earnings release. The company is expected to report EPS up by double digits from the prior-year quarter. Any recent changes to analyst estimates for JD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. In terms of valuation, JD is currently trading at a Forward P/E ratio of 30.03. For comparison, its industry has an average Forward P/E of 24.38, which means JD is trading at a premium to the group.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Stock Picks for Week of October 14, 2019
Roku, Inc. (ROKU - Free Report) , is involved in creating a streaming platform for delivering entertainment to television. Over the past 90 days, the Zacks Consensus Estimate for ROKU's full-year earnings has moved 13.04% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Wall Street will be looking for positivity from ROKU as it approaches its next earnings report date. Over the past month, the Zacks Consensus EPS estimate has moved 6.72%. According to our latest data, ROKU has moved higher by triple digits on a year-to-date basis. It looks to continue its solid performance.
JD.com, Inc. (JD - Free Report) , operates as an online direct sales company in China. It’s considered the Amazon of China. Investors will be hoping for strength from JD as it approaches its next earnings release. The company is expected to report EPS up by double digits from the prior-year quarter. Any recent changes to analyst estimates for JD should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. In terms of valuation, JD is currently trading at a Forward P/E ratio of 30.03. For comparison, its industry has an average Forward P/E of 24.38, which means JD is trading at a premium to the group.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>